115 related articles for article (PubMed ID: 15149145)
21. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
22. Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
Tuyaerts S; Aerts JL; Corthals J; Neyns B; Heirman C; Breckpot K; Thielemans K; Bonehill A
Cancer Immunol Immunother; 2007 Oct; 56(10):1513-37. PubMed ID: 17503040
[TBL] [Abstract][Full Text] [Related]
23. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells in vaccination therapies of human malignant disease.
Reichardt VL; Brossart P; Kanz L
Blood Rev; 2004 Dec; 18(4):235-43. PubMed ID: 15501552
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell-based cancer immunotherapy targeting MUC-1.
Wierecky J; Mueller M; Brossart P
Cancer Immunol Immunother; 2006 Jan; 55(1):63-7. PubMed ID: 15864588
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
Avigan D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
[TBL] [Abstract][Full Text] [Related]
27. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
Yannelli JR; Wroblewski JM
Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
29. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
[TBL] [Abstract][Full Text] [Related]
30. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
Mosolits S; Nilsson B; Mellstedt H
Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
[TBL] [Abstract][Full Text] [Related]
31. New developments in dendritic cell-based vaccinations: RNA translated into clinics.
Grünebach F; Müller MR; Brossart P
Cancer Immunol Immunother; 2005 Jun; 54(6):517-25. PubMed ID: 15838706
[TBL] [Abstract][Full Text] [Related]
32. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
Schultze JL; Grabbe S; von Bergwelt-Baildon MS
Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell-based cancer vaccination: quo vadis?
Dauer M; Schnurr M; Eigler A
Expert Rev Vaccines; 2008 Sep; 7(7):1041-53. PubMed ID: 18767953
[TBL] [Abstract][Full Text] [Related]
34. Future of idiotypic vaccination for B-cell lymphoma.
de Cerio AL; Inogés S
Expert Rev Vaccines; 2009 Jan; 8(1):43-50. PubMed ID: 19093772
[TBL] [Abstract][Full Text] [Related]
35. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
36. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
[TBL] [Abstract][Full Text] [Related]
37. New understanding of immunological mechanisms.
Saalmüller A
Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
[TBL] [Abstract][Full Text] [Related]
38. Cellular immunotherapy with dendritic cells in cancer: current status.
Nencioni A; Brossart P
Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
[TBL] [Abstract][Full Text] [Related]
39. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
40. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
